Skip to content
In English |
En español
National Cancer Institute
at the National Institutes of Health
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Popular Resources
Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-8 of 8 for your search:
Drug:
imetelstat sodium
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GRN163L CP14A010
, NCT00732056
2.
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP14B012
, NCT01137968
3.
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP14B014
, NCT01256762
4.
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GRN163L CP05-101
, NCT00310895
5.
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GRN163L CP14A005
, NCT00510445
6.
Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP14A004
, NCT00594126
7.
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GRN163L CP14A011
, NCT00718601
8.
Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GRN163L CP04-151
, NCT00124189
Select All on Page
Help with Results
We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat
NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map
Other Versions of this Site:
Mobile
|
Español
Follow Us:
Twitter
YouTube
Facebook
RSS
NIH…Turning Discovery Into Health
®
Mobile | Español
Mobile | Español
